Skip to main content

Table 1 Modified MCP 841 Protocol

From: Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia with e1a3 BCR-ABL1 transcript in a Nigerian with sickle cell anemia: a case report

Phase and duration Medication Dosage
Route and schedule
Induction 1A
29 days
1. Pre-induction prednisolone 60 mg/m2 PO day 1–7
2. Prednisolone 40 g/m2 PO day 8–28
3. Vincristine 1.4 mg/m2 IV day 8, 15, 22, 29
4. Daunorubicin 20 mg/m2 IV day 8, 15, 29
5. l-Asparaginase 6000 U/m2 SC day 8, 10, 12, 14, 16, 18, 20, 22, 24, 26
6. CNS prophylaxis: *Triple prophylaxis  
   Methotrexate 12 mg; IT day 8, 15, 22, 29
   Cytarabine 30 mg; IT day 8, 15, 22, 29
   Hydrocortisone 20 mg; IT day 8, 15, 22, 29
Induction 2A
28 days
Cyclophosphamide 750 mg/m2; IV day 1, 15
6-Mercaptopurine 60 mg/m2 ; PO day 1–28
Cytarabine 75 mg/m2; IV day 1–4, 8–11, 15–18, 22–25
CNS prophylaxis as Induction 1A IT day 8, 15, 22, 29
Induction 2B
56 days
Cyclophosphamide
6-Mercaptopurine
750 mg/m2; IV day 1, 15
60 mg/m2; PO day 1–56
Methotrexate Low risk: 20 mg/m2;
IV day 1, 11, 21, 31, 41
High risk: Start at 100 mg/m2 and increase by 50 mg/m2 up to 5 doses
CNS prophylaxis as in Induction 1A IT day 8, 15, 22, 29
Induction 1B
28 days
Repeat Induction 1A As in Induction 1A
Consolidation
28 days
Cytarabine
Vincristine
Cyclophosphamide
Daunorubicin
6-Mercaptopurine
100 mg/m2; SC 12-hourly day 1–3, 15–17
1.4 mg/m2; IV day 1, 15
750 mg/m2; IV day 1
20 mg/m2; IV day 15
75 mg/m2; PO day 1–7, 15–21
CNS prophylaxis:- Drugs as in Induction 1A IT day 1
Maintenance
8 cycles for B-ALL (12 weeks per cycle)
96 weeks
Prednisolone
Vincristine
Daunorubicin
l-Asparaginase
6-Mercaptopurine
Methotrexate
40 g/m2; PO day 1–7
1.4 mg/m2; IV day 1
20 mg/m2; IV day 1
6000 U/m2; SC day 1, 3, 5, 7
75 mg/m2; PO daily × 12 doses
15 mg/m2; PO weekly
CNS prophylaxis:- Methotrexate 12 mg; IT day 1 of each cycle